MARKET

CCCC

CCCC

C4 Therapeutics, Inc.
NASDAQ
2.560
-0.140
-5.19%
Closed 19:55 03/23 EDT
OPEN
2.760
PREV CLOSE
2.700
HIGH
2.810
LOW
2.550
VOLUME
2.70M
TURNOVER
0
52 WEEK HIGH
3.820
52 WEEK LOW
1.085
MARKET CAP
249.80M
P/E (TTM)
-2.0212
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CCCC last week (0316-0320)?
Weekly Report · 1d ago
Weekly Report: what happened at CCCC last week (0309-0313)?
Weekly Report · 03/16 10:04
C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact
Seeking Alpha · 03/10 11:49
C4 Therapeutics grants 85,480 inducement stock options to new employee
Reuters · 03/09 20:01
C4 THERAPEUTICS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 03/09 20:01
Weekly Report: what happened at CCCC last week (0302-0306)?
Weekly Report · 03/09 10:05
C4 Therapeutics Publishes Corporate Presentation on Targeted Protein Degradation Pipeline in Oncology and INN Diseases
Reuters · 03/03 12:04
Weekly Report: what happened at CCCC last week (0223-0227)?
Weekly Report · 03/02 10:04
More
About CCCC
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).

Webull offers C4 Therapeutics Inc stock information, including NASDAQ: CCCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCCC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CCCC stock methods without spending real money on the virtual paper trading platform.